Neokidney Dialysis System Meets Phase 1 and 2 Goals
The portable hemodialysis device successfully cleared safety and efficacy milestones in early clinical testing.
Updated on Oct. 24, 2026 in Stroke
Live Poll
Do you trust that new portable medical technology will improve your independence in managing chronic conditions?
The Neokidney portable hemodialysis system demonstrated efficacy and safety in the initial two phases of the RENEW-HD trial. Researchers reported successful data from 474 sessions as they prepare for the next stage of development.
Why it matters
The system aims to increase patient autonomy by allowing dialysis without external water connections. Its successful performance suggests a future for more flexible treatment options for patients with kidney disease.
The device weighs 13 kilograms and regenerates 4.5 liters of dialysate at a flow rate of 300 milliliters per minute. Participants achieved a mean single-pool Kt/V of 0.74 per 2-hour treatment.
The players
Neokidney
This organization develops portable hemodialysis technology designed to improve quality of life for renal patients.
ASN Kidney Week
This annual medical conference serves as a global gathering for researchers and clinicians to share advancements in nephrology.
The details
Using zirconium phosphate, the device captures ammonium from urea in a closed-loop system that operates independently of water supply or drainage. While three patients experienced ionized calcium levels above 1.5 mmol/L, investigators attributed the elevations to high dialysate calcium concentrations and plan to adjust these levels for future testing.
Timeline
August 31, 2026: Data cutoff for 474 completed study sessions.
October 21-25, 2026: RENEW-HD data presented at ASN Kidney Week.
End of 2026: Expected start of phase 3 trials.
The Big Picture
This development follows the protocols established by the RENEW-HD trial to validate portable dialysis technology. It marks a shift toward miniaturized, self-contained medical systems that replace the bulky infrastructure historically required for chronic kidney treatment.
The device offers potential for greater lifestyle flexibility by removing the need for permanent connections to home or center water lines. Patients should monitor for future updates on device availability and clinical trial outcomes.
The takeaway
This technology represents a significant step toward making renal therapy portable and less dependent on clinical facilities. Researchers are currently focusing on fine-tuning calcium concentrations to ensure patient safety before broader autonomous testing.
What happens next
Phase 3 trials are expected to begin by the end of 2026, focusing on autonomous use across approximately 500 additional sessions.
Further reading
Learn more about the latest innovations in renal care on our Stroke page.
Source note: This article includes information reported by Hcplive.
Live Poll
Do you trust that new portable medical technology will improve your independence in managing chronic conditions?
